|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR design optimization for solid tumors is crucial due to the absence of truly restricted antigen expression and potential safety concerns with "on-target off-tumor" activity.
|
29061641 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR T-cell Therapy for Solid Tumors?
|
30291124 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
|
30999624 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although CAR T cell therapy mediates robust responses in patients with hematological malignancies, this approach has been less effective for treating patients with solid tumors.
|
30842774 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although CAR-T cell therapy did not have satisfactory responses in solid tumors, researchers were still holding an optimistic attitude towards its future efficacy with more modifications of its structure.
|
30886654 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Amph-Ligand Vaccine Enhances CAR-T Cell Activity against Solid Tumors.
|
31324609 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
|
31707682 |
2020 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Application of CAR T cells for the treatment of solid tumors.
|
31383408 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Application of the CAR targeting strategy in solid tumors is challenged by the need for adequate target antigens.
|
30483473 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD56-CAR-T cell therapy is a safe and effective approach and may be an option for children with solid tumors who are nonresponsive to conventional radiotherapy and chemotherapy, or are unsuitable for hematopoietic stem cell transplantation.
|
31651858 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor-modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors.
|
29769444 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest.
|
30298067 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors.
|
25621840 |
2015 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy.
|
29423418 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors.
|
30636882 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Due to their high heterogeneity and complex tumor microenvironment, the treatment of solid tumors by CAR-T cell technology is limited.
|
31497363 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Effective deployment of CAR T-cell immunotherapy for solid tumors has proven challenging to date, due to a series of formidable hurdles.
|
31038366 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Further evaluation showed that pSM3-CAR effectively caused tumor necrosis, providing new options for improved CAR-T therapy in solid tumors.
|
26961900 |
2016 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we demonstrate an approach to enhancing CAR-T function in solid tumors by directly vaccine-boosting donor cells through their chimeric receptor in vivo.
|
31296767 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we provide our perspective on how to improve the success of CAR T therapy in solid tumors by focusing on the aspects of target selection and the related TME in CAR T cell design, especially stressing the interplay between them.
|
30906625 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results.
|
29433552 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
|
29634393 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, CAR-T cell therapy has shown limited efficacy for the treatment of solid tumors.
|
31142602 |
2019 |